Study demonstrates that TransCode’s lead therapeutic candidate, TTX-MC138, reduces tumor cell capacity for self-renewalBOSTON, Sept. 10, 2024 (GLOBE NEWSWIRE) --…
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 9, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…
Milestone marks a significant step toward producing mRNA vaccines in Canada by 2025 CAMBRIDGE, MA / ACCESSWIRE / September 9,…
CALGARY, Alberta, Sept. 06, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX…
TEMPE, Ariz., Sept. 6, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in August for the 12th consecutive month…
A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including a new COVID-19 vaccine, Prostate…
NEW YORK, Sept. 5, 2024 /PRNewswire/ -- Report with market evolution powered by AI- The global prosthetic robot arm market size…
NEW YORK, Sept. 5, 2024 /PRNewswire/ -- The Bristal Assisted Living communities are utilizing innovative AI technologies to increase the…
Business Activity Index at 53.3%; New Orders Index at 53%; Employment Index at 50.2%; Supplier Deliveries Index at 49.6% TEMPE,…
Moderna's updated COVID-19 mRNA vaccine will be available for the 2024-2025 vaccination season, pending a European Commission authorization decision CAMBRIDGE,…
